Preparations and therapy of intrathecal inflammatory disease
A method for prevention and/or treatment of inflammatory/edematous diseases of the central nervous system or increased intracranial pressure comprises intrathecal administration of at least one anti-inflammatory and/or anti-edematous agent.
1 ) A method for prevention and/or treatment of inflammatory/edematous diseases of the central nervous system or increased intracranial pressure comprising intrathecal administration of at least one anti-inflammatory and/or anti-edematous agent.
2 ) A method according to claim 1 , wherein the inflammatory/edematous diseases of the central nervous system is stroke, in particular ischemic stroke.
3 ) A method according to claim 1 , wherein the anti-inflammatory and/or anti-edematous agent is a glucocorticoid.
4 ) A method according to claim 2 , wherein the glucocorticoid is in its base form.
5 ) A method according to claim 3 , wherein the glucocorticoid is selected from Betamethasone, Cortisone, Dexamethasone, Fluprednisolone, Hydrocortisone, Meprednisolone, Paramethasone, Prednisolone and/or Triamcinolone.
6 ) A method according to claim 1 , wherein the administered volume is about 1 ml to about 30 ml, preferably between about 5 ml and about 10 ml.
7 ) A method according to claim 1 , wherein the administered dose of anti-inflammatory and/or anti-edematous agent is 0,1 mg to 20 mg, in particular 1 to 5 mg.
8 ) A method according to claim 1 , wherein the administration is performed up to 24 hours after stroke
9 ) A method according to claim 8 , wherein the administration is performed between 4 and 24 hours after stroke.
10 ) A pharmaceutical preparation containing at least one anti-inflammatory and/or anti-edematous agent in therapeutic, non toxic dosage, in sterile, pyrogen-free aqueous solution, for intrathecal administration.
11 ) A pharmaceutical preparation according to claim 10 , wherein the anti-inflammatory and/or anti-edematous agent is a glucocorticoid in its base form or acetonide form or ester form, preferably base form or acetonide form.
12 ) A liquid pharmaceutical preparation containing at least one anti-inflammatory and/or anti-edematous agent in therapeutic, non toxic dosage at a concentration not soluble in water, wherein a therapeutically effective proportion of the drug is not contained in supramolecular structures.
13 ) A liquid pharmaceutical preparation containing at least one anti-inflammatory and/or anti-edematous agent in therapeutic, non toxic dosage at a concentration not soluble in water, and a X-ray contrast agent.
14 ) A liquid preparation according to claim 13 , wherein the pharmaceutical preparation is an aqueous solution.
15 ) A method for the treatment of a brain infarct, trauma of the central nervous system and/or conditions following central nervous system surgery, comprising administering intrathecally a preparation of claim 10 .
16 ) A kit consisting of at least one anti-inflammatory and/or anti-edematous agent in therapeutic, non toxic dosage, preferably in sterile pyrogen-free stable solution (A) and at least one pharmaceutical preparation